A new study confirms that metal-on-metal hip implants like the ASR Resurfacing devices manufacture by DePuy have much higher failure rates, sparking more calls by DePuy hip implant lawyers for a ban on these devices.

The study, which has been published in The Lancet medical Journal, analyzed data from the National Joint Registry of England and Wales.  The data included more than 400,000 hip replacements, including 31,171 all-metal hip implants.

The researchers say there is no confusion in the findings.  The all metal implants simply have a much failure rate compared to other devices.

The failure rate was found to be particularly high in larger-head implants.  Devices that were implanted in women also seemed to have a much higher failure rate, and in some cases, these increases were up to 4 times higher.  According to the study, there is a 6.2% chance that a person implanted with a metal-on-metal implant will suffer a failure of the device.  These patients will require a revision surgery within 5 years.  That is a rate that is about 3 times greater than for other devices.

In 2010, the Food and Drug Administration officially announced that the failure rates and revision surgery risks with metal-on-metal hip implants manufactured by DePuy are much higher, with a revision rate of about 12% in 5 years.

Metal-on-metal implants, like the ASR XL Acetabular System and the ASR Hip Resurfacing System manufactured by DePuy Orthopedics, have also been linked to a number of other health problems.  Studies have shown that some of the metal ions in these implants can leak into the bloodstream over a period of time.  Patients have suffered symptoms of toxicity, after ions of chromium and cobalt from the devices leaked into their system.  Doctors advise persons who have these implants to get themselves checked for metal ions in their bloodstream.